重组Anti-BRCA2抗体[EPR23442-43]
Anti-BRCA2 antibody [EPR23442-43]
- RabMAb
- KO Validated
- Recombinant
- 了解详情
5
(1 Review)
|
(4 Publications)
Rabbit Recombinant Monoclonal BRCA2 antibody. Suitable for WB and reacts with Human samples. Cited in 4 publications.
查看别名
FACD, FANCD1, BRCA2, Breast cancer type 2 susceptibility protein, Fanconi anemia group D1 protein
- WB
Lab
Western blot - Anti-BRCA2 antibody [EPR23442-43] (AB239375)
Anti-BRCA2 antibody [EPR23442-43] (ab239375) staining at 1/500 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab239375 was shown to bind specifically to BRCA2. A band was observed at 290 kDa in wild-type MCF7 cell lysates with no signal observed at this size in BRCA2 knockout cell line ab286285 (knockout cell lysate ab300210). To generate this image, wild-type and BRCA2 knockout MCF7 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween$®$ 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
All lanes:
Western blot - Anti-BRCA2 antibody [EPR23442-43] (ab239375) at 1/500 dilution
Lane 1:
Wild-type MCF7 cell lysate at 20 µg
Lane 2:
Western blot - Human BRCA2 knockout MCF7 cell lysate (ab300210) at 20 µg
Lane 3:
Jurkat cell lysate at 20 µg
Lane 4:
PC-3 cell lysate at 20 µg
Lane 5:
HT-29 cell lysate at 20 µg
Secondary
Lanes 1 - 5:
Goat anti-Rabbit IgG H&L 800CW at 1/20000 dilution
Lanes 1 - 5:
Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Observed band size: 290 kDa
false
- WB
Lab
Western blot - Anti-BRCA2 antibody [EPR23442-43] (AB239375)
Negative control : Capan-1 (PMID : 16251802). Lysates were freshly made and used for Western blotting immediately to minimize protein degradation. Blocking and diluting buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-BRCA2 antibody [EPR23442-43] (ab239375)
Lane 1:
HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 100 µg
Lane 2:
Capan-1 (human pancreas adenocarcinoma epithelial cell) whole cell lysate at 100 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution
Predicted band size: 384 kDa
false
Exposure time: 180s
反应性数据
产品详情
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存时间
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (4)
Recent publications for all applications. Explore the full list and refine your search
Molecular brain 18:78 PubMed41068896
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of translational medicine 23:652 PubMed40514657
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancer chemotherapy and pharmacology 92:71-81 PubMed37272931
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular and molecular medicine 27:634-649 PubMed36753396
2023
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com